REGENXBIO Inc. (NASDAQ:RGNX) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have covered the stock in the last year is $34.33.

Several research firms recently weighed in on RGNX. Evercore ISI began coverage on shares of REGENXBIO in a research note on Wednesday. They issued an “outperform” rating for the company. BidaskClub raised shares of REGENXBIO from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Investment Research raised shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research report on Saturday. Finally, Chardan Capital increased their price target on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th.

REGENXBIO (NASDAQ RGNX) traded up 3.50% on Wednesday, hitting $22.15. The company had a trading volume of 176,545 shares. The stock’s market cap is $684.30 million. The firm’s 50 day moving average price is $19.63 and its 200 day moving average price is $19.36. REGENXBIO has a 12-month low of $9.84 and a 12-month high of $24.55.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. The business had revenue of $6.56 million during the quarter. Equities analysts predict that REGENXBIO will post ($2.93) earnings per share for the current fiscal year.

In related news, CFO Vittal Vasista sold 3,100 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $18.75, for a total value of $58,125.00. Following the completion of the transaction, the chief financial officer now owns 107,512 shares of the company’s stock, valued at $2,015,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kenneth T. Mills sold 6,500 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $18.66, for a total transaction of $121,290.00. Following the completion of the transaction, the insider now directly owns 112,000 shares of the company’s stock, valued at approximately $2,089,920. The disclosure for this sale can be found here. Insiders sold 19,200 shares of company stock valued at $368,746 in the last three months. Company insiders own 17.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in REGENXBIO during the first quarter valued at about $612,000. JPMorgan Chase & Co. raised its position in REGENXBIO by 17.6% in the first quarter. JPMorgan Chase & Co. now owns 1,175,794 shares of the biotechnology company’s stock valued at $22,693,000 after buying an additional 176,047 shares during the period. Oxford Asset Management acquired a new position in REGENXBIO during the first quarter valued at about $206,000. Mirae Asset Global Investments Co. Ltd. raised its position in REGENXBIO by 217.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 75,591 shares of the biotechnology company’s stock valued at $1,459,000 after buying an additional 51,802 shares during the period. Finally, Trexquant Investment LP acquired a new position in REGENXBIO during the first quarter valued at about $485,000. 67.84% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/16/regenxbio-inc-rgnx-given-average-recommendation-of-buy-by-brokerages.html.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.